placeholder
and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Document type
Language
Year
  • 1
    Language: English
    In: Histopathology, 2015-09, Vol.67 (3), p.368-377
    Description: Aims Due to the growing number of somatostatin receptor (SSTR) targeting analogues and radiopeptides used for the diagnosis and therapy of neuroendocrine neoplasms (NEN), the assessment of SSTR subtype status has increasingly gained predictive value. In pathology, the SSTR protein levels are detected routinely by immunohistochemistry (IHC); however, a lack of a standardized evaluation system persists. Thus, in the present investigation, three well‐established semi‐quantitative scoring systems [immunoreactive score (IRS), human epidermal growth factor receptor 2 (HER2)/neu score, H score] used commonly for SSTR‐IHC evaluation in NEN were compared. Methods and results A total of 240 formalin‐fixed, paraffin‐embedded tumour samples from 90 patients with bronchopulmonary NEN were examined by IHC and quantitative reverse transcription–polymerase chain reaction (qRT–PCR) for SSTR1, 2A, 3, 4 and 5 expression. Using both methods, SSTR1, 2A and 5 were the most frequently expressed subtypes. For all SSTR subtypes, all three scores correlated well with each other and with qRT–PCR data. However, the IRS was the most meaningful score with the best correlation to mRNA levels. Conclusions Because a unified IHC scoring system for SSTR analysis is needed urgently to optimize the theranostics of NEN, among the scores tested, the IRS seems to be the most suitable according to our results. It provides sufficient accuracy combined with high practicability.
    Subject(s): Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Bronchial Neoplasms - genetics ; Bronchial Neoplasms - metabolism ; Bronchial Neoplasms - pathology ; Comparative analysis ; H score ; HER2/neu score ; Humans ; Immunohistochemistry ; Immunohistochemistry - methods ; immunoreactive score ; lung ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Neuroendocrine Tumors - genetics ; Neuroendocrine Tumors - metabolism ; Neuroendocrine Tumors - pathology ; neuroendocrine tumours ; Receptor, ErbB-2 - metabolism ; Receptors, Somatostatin - classification ; Receptors, Somatostatin - genetics ; Receptors, Somatostatin - metabolism ; receptors/somatostatin ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; RNA, Neoplasm - genetics ; RNA, Neoplasm - metabolism ; Tumors
    ISSN: 0309-0167
    E-ISSN: 1365-2559
    Source: Academic Search Ultimate
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Nature genetics, 2018-07, Vol.50 (7), p.979-989
    Description: We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins that mechanistically regulate tumor cell state, as assessed from systematic drug perturbation assays. We validated the approach on a cohort of 212 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare malignancy originating in the pancreas and gastrointestinal tract. The analysis identified several master regulator proteins, including key regulators of neuroendocrine lineage progenitor state and immunoevasion, whose role as critical tumor dependencies was experimentally confirmed. Transcriptome analysis of GEP-NET-derived cells, perturbed with a library of 107 compounds, identified the HDAC class I inhibitor entinostat as a potent inhibitor of master regulator activity for 42% of metastatic GEP-NET patients, abrogating tumor growth in vivo. This approach may thus complement current efforts in precision oncology.
    Subject(s): Antineoplastic Agents - pharmacology ; Benzamides - pharmacology ; Biological Sciences ; Biologiska vetenskaper ; Cell Line, Tumor ; Cohort Studies ; Gastrointestinal Tract - drug effects ; Gastrointestinal Tract - metabolism ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylases - metabolism ; Humans ; Intestinal Neoplasms - drug therapy ; Intestinal Neoplasms - genetics ; Natural Sciences ; Naturvetenskap ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - genetics ; Pancreas - drug effects ; Pancreas - metabolism ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Precision Medicine - methods ; Pyridines - pharmacology ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - genetics
    ISSN: 1061-4036
    ISSN: 1546-1718
    E-ISSN: 1546-1718
    Source: Single Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: PloS one, 2021, Vol.16 (2), p.e0246939
    Description: The complement component C5a and its receptor C5aR1 are involved in the development of numerous inflammatory diseases. In addition to immune cells, C5aR1 is expressed in neoplastic cells of multiple tumour entities, where C5aR1 is associated with a higher proliferation rate, advanced tumour stage, and poor patient outcomes. The aim of the present study was to obtain a broad expression profile of C5aR1 in human non-neoplastic and neoplastic tissues, especially in tumour entities not investigated in this respect so far. For this purpose, we generated a novel polyclonal rabbit antibody, {5227}, against the carboxy-terminal tail of C5aR1. The antibody was initially characterised in Western blot analyses and immunocytochemistry using transfected human embryonic kidney (HEK) 293 cells. It was then applied to a large series of formalin-fixed, paraffin-embedded non-neoplastic and neoplastic human tissue samples. C5aR1 was strongly expressed by different types of immune cells in the majority of tissue samples investigated. C5aR1 was also present in alveolar macrophages, bronchial, gut, and bile duct epithelia, Kupffer cells, occasionally in hepatocytes, proximal renal tubule cells, placental syncytiotrophoblasts, and distinct stem cell populations of bone marrow. C5aR1 was also highly expressed in the vast majority of the 32 tumour entities investigated, where a hitherto unappreciated high prevalence of the receptor was detected in thyroid carcinomas, small-cell lung cancer, gastrointestinal stromal tumours, and endometrial carcinomas. In addition to confirming published findings, we found noticeable C5aR1 expression in many tumour entities for the first time. Here, it may serve as an interesting target for future therapies.
    Subject(s): Amino acids ; Antibodies ; Antigens ; Cell culture ; Cell receptors ; Cellular biology ; Complement (Immunology) ; Complement component C5a ; Cytology ; Editing ; Genetic drift ; Health aspects ; Hospitals ; Human tissues ; Identification and classification ; Immunohistochemistry ; Innate immunity ; Laboratories ; Medicine and Health Sciences ; Metastases ; Methods ; Microorganisms ; Neutrophils ; Pathology ; Peptides ; Pharmacology ; Receptors ; Reviews ; Staining ; Surgery ; Toxicology ; Tumors
    ISSN: 1932-6203
    E-ISSN: 1932-6203
    Source: Academic Search Ultimate
    Source: PubMed Central
    Source: DOAJ Directory of Open Access Journals - Not for CDI Discovery
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Journal of cancer research and clinical oncology, 2019-10, Vol.145 (10), p.2481-2493
    Description: Pancreatic adenocarcinoma (PAC) represents one of the most fatal types of cancer with an exceptionally poor prognosis, underscoring the need for improved diagnostic and treatment approaches. An over-expression of somatostatin receptors (SST) as well as of the chemokine receptor CXCR4 has been shown for many tumour entities. Respective expression data for PAC, however, are scarce and contradictory.Overall, 137 tumour samples from 70 patients, 26 of whom were diagnosed with PAC and 44 with pancreatic neuroendocrine tumour (PanNET), were compared in terms of SST and CXCR4 expression by immunohistochemical analysis using well-characterized rabbit monoclonal antibodies.Only SST1 and CXCR4 expression was detected in PAC tumours, with SST1 present in 42.3% and CXCR4 in 7.7% of cases. However, the overall staining intensity was very weak. In contrast to the tumour cells, in many PAC cases, tumour capillaries exhibited strong SST3, SST5, or CXCR4 expression. In PanNETs, SST2 was the most-prominently expressed receptor, observed in 75.0% of the tumours at medium–strong intensity. SST5, SST1, and CXCR4 expression was detected in 20.5%, 15.9%, and 11.4% of PanNET cases, respectively, but the staining intensity was only weak. SST2 positivity in PanNET, but not in PAC, was associated with favourable patient outcomes.SST or CXCR4 expression in PAC is clearly of no therapeutic relevance. However, indirect targeting of these tumours via SST3, SST5, or CXCR4 on tumour microvessels may represent a promising additional therapeutic strategy.
    Subject(s): Adenocarcinoma ; Analysis ; Cancer Research ; CXCR4 ; Hematology ; Immunohistochemistry ; Internal Medicine ; Life Sciences & Biomedicine ; Medicine & Public Health ; Monoclonal antibodies ; Oncology ; Pancreatic adenocarcinoma ; Pancreatic cancer ; Pancreatic neuroendocrine tumour ; Science & Technology ; Somatostatin receptor
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Source: Web of Science - Science Citation Index Expanded - 2019〈img src="http://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /〉
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: International journal of molecular sciences, 2019-11-01, Vol.20 (21), p.5261
    Description: GPR68 (OGR1) belongs to the proton-sensing G protein-coupled receptors that are involved in cellular adaptations to pH changes during tumour development. Although expression of GPR68 has been described in many tumour cell lines, little is known about its presence in human tumour entities. We characterised the novel rabbit monoclonal anti-human GPR68 antibody 16H23L16 using various cell lines and tissue specimens. The antibody was then applied to a large series of formalin-fixed, paraffin-embedded normal and neoplastic human tissue samples. Antibody specificity was demonstrated in a Western blot analysis of GPR68-expressing cells using specific siRNAs. Immunocytochemical experiments revealed pH-dependent changes in subcellular localisation of the receptor and internalisation after stimulation with lorazepam. In normal tissue, GPR68 was present in glucagon-producing islet cells, neuroendocrine cells of the intestinal tract, gastric glands, granulocytes, macrophages, muscle layers of arteries and arterioles, and capillaries. GPR68 was also expressed in neuroendocrine tumours, where it may be a positive prognostic factor, in pheochromocytomas, cervical adenocarcinomas, and endometrial cancer, as well as in paragangliomas, medullary thyroid carcinomas, gastrointestinal stromal tumours, and pancreatic adenocarcinomas. Often, tumour capillaries were also strongly GPR68-positive. The novel antibody 16H23L16 will be a valuable tool for basic research and for identifying GPR68-expressing tumours during histopathological examinations.
    Subject(s): Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Antibodies, Monoclonal - immunology ; antibody ; Antibody Affinity ; Biochemistry & Molecular Biology ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - immunology ; Biomarkers, Tumor - metabolism ; Cell Line, Tumor ; Chemistry ; Chemistry, Multidisciplinary ; Female ; GPR68 ; HEK293 Cells ; Humans ; Immunoassay - methods ; Immunoassay - standards ; immunohistochemistry ; Life Sciences & Biomedicine ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Male ; Middle Aged ; neuroendocrine ; OGR1 ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Physical Sciences ; Rabbits ; Receptors, G-Protein-Coupled - genetics ; Receptors, G-Protein-Coupled - immunology ; Receptors, G-Protein-Coupled - metabolism ; Science & Technology ; Sensitivity and Specificity ; tumours
    ISSN: 1422-0067
    E-ISSN: 1422-0067
    Source: Academic Search Ultimate
    Source: Web of Science - Science Citation Index Expanded - 2019〈img src="http://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /〉
    Source: PubMed Central
    Source: DOAJ Directory of Open Access Journals - Not for CDI Discovery
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Journal of cancer research and clinical oncology, 2018-10, Vol.144 (10), p.1921-1932
    Description: Lung cancer is highly prevalent and has an especially poor prognosis. Thus, new diagnostic and therapeutic targets are necessary. Two potential targets are somatostatin receptors (SST), which are overexpressed in well-differentiated neuroendocrine neoplasms, and the chemokine receptor CXCR4, which is present mainly in highly proliferative and advanced tumours. Although their expression is relatively well characterized in small cell lung cancer (SCLC), in non-small cell lung cancer (NSCLC), data on SST and CXCR4 expression are scarce and contradictory.We comparatively evaluated 83 tumour samples from a total of 57 lung cancer patients, of which 22 had adenocarcinoma (ADC), 21 had squamous cell carcinoma (SQC), and 15 had SCLC. Samples were evaluated for SST and CXCR4 expression using immunohistochemistry with well-characterized rabbit monoclonal antibodies.In the samples investigated, the most prominently expressed receptors were CXCR4 and SST5. Specifically, CXCR4 was detected with high expression intensity in more than 60% of ADC samples, about 90% of SQC, and 100% of SCLC. SST5 was present in about 75% of ADC and SQC samples and in more than 90% of SCLC. Although not noticeably expressed in ADC and SQC samples, SST2 was detected in 50% of SCLC cases, with a subset of patients displaying exceptionally high expression. The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples.CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.
    Subject(s): Adenocarcinoma ; Adenocarcinoma - metabolism ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Analysis ; Biomarkers, Tumor - metabolism ; Cancer Research ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - surgery ; Chemokine receptor ; CXCR4 ; Female ; Follow-Up Studies ; Hematology ; Humans ; Immunohistochemistry ; Internal Medicine ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Non-small cell lung cancer ; Oncology ; Prognosis ; Receptors, CXCR4 - metabolism ; Signal Transduction ; Small cell lung cancer ; Small Cell Lung Carcinoma - metabolism ; Small Cell Lung Carcinoma - pathology ; Small Cell Lung Carcinoma - surgery ; Somatostatin - metabolism ; Somatostatin receptors ; Squamous cell carcinoma ; Survival Rate
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Scientific reports, 2019-03-13, Vol.9 (1), p.4339
    Description: Somatostatin receptors (SST), especially SST2A, are known for their overexpression in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). The chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced tumors. However, comprehensive data are still lacking on potential differences in SST or CXCR4 expression pattern in GEP-NEN in dependence on the place of origin. Overall, 412 samples from 165 GEP-NEN patients, comprising both primary tumors (PT) and metastases (MTS), originating from different parts of the gastrointestinal tract or the pancreas were evaluated for SST and CXCR4 expression by means of immunohistochemistry using monoclonal antibodies. SST2A was present in 85% of PT with a high intensity of expression, followed by SST5 (23%), CXCR4 (21%), SST3 (10%), SST1 (9%), and SST4 (4%). PT displayed higher SST2A and chromogranin A (CgA) expression levels than MTS. In both PT and MTS lower SST2A and CgA expression levels were found in tumors originating from the appendix or colon, compared to tumors from other origins. Tumors derived from appendix or colon were associated with significantly worse patient outcomes. Positive correlations were noted between SST2A and CgA as well as between CXCR4 and Ki-67 expression levels. SST2A and CgA negativity of the tumors was significantly associated with poor patient outcomes. All in all, SST2A was the most prominent receptor expressed in the GEP-NEN samples investigated. However, expression levels varied considerably depending on the location of the primary tumor.
    Subject(s): Adolescent ; Adult ; Aged ; Aged, 80 and over ; Appendix ; Chemokines ; Child ; Clinical outcomes ; Colon ; CXCR4 protein ; Female ; Gastrointestinal Neoplasms - metabolism ; Gastrointestinal Neoplasms - pathology ; Gastrointestinal tract ; Humans ; Immunohistochemistry ; Male ; Metastases ; Middle Aged ; Monoclonal antibodies ; Multidisciplinary Sciences ; Neuroendocrine Tumors - metabolism ; Neuroendocrine Tumors - pathology ; Pancreas ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Receptors, CXCR4 - metabolism ; Receptors, Somatostatin - metabolism ; Science & Technology ; Science & Technology - Other Topics ; Somatostatin ; Somatostatin receptors ; Tumors ; Young Adult
    ISSN: 2045-2322
    E-ISSN: 2045-2322
    Source: Nature Open Access
    Source: Academic Search Ultimate
    Source: Web of Science - Science Citation Index Expanded - 2019〈img src="http://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /〉
    Source: PubMed Central
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: World journal of gastroenterology : WJG, 2009, Vol.15 (46), p.5867-5870
    Description: Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis many of them are already advanced and difficult to treat. We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. This resulted in a significant downstaging of the tumor and allowed its sub- sequent complete surgical removal. Follow-up for eighteen months revealed a complete remission. This is the first report on neoadjuvant PRRT in a neuroendocrine neoplasm with subsequent successful complete resection.
    Subject(s): Adult ; Case Report ; Combined Modality Therapy ; Computed tomography ; Endocrine pancreatic carcinoma ; Female ; Humans ; Lymph Nodes - pathology ; Lymphatic Metastasis - pathology ; Molecular imaging ; Neoadjuvant Therapy - methods ; Neodjuvant treatment ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - radiotherapy ; Neuroendocrine Tumors - surgery ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - surgery ; Pancreatic surgery ; Peptide receptor radionuclide therapy ; Radioisotopes - therapeutic use ; Receptor pancreatic endocrine tumor ; Receptors, Peptide - metabolism ; Treatment Outcome ; 受体 ; 手术切除 ; 放射性核素 ; 治疗 ; 神经内分泌 ; 肽 ; 肿瘤 ; 胰腺
    ISSN: 1007-9327
    E-ISSN: 2219-2840
    Source: PubMed Central
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Annals of surgical oncology, 2020-05, Vol.27 (5), p.1348-1355
    Description: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and risk factors for death after radical surgery. Secondary aims are the description of median recurrence-free survival (RFS) and of the role of adjuvant chemotherapy. Multicenter analysis of a series of stage I-III GEP-NEN G3 patients receiving radical surgery (R0/R1) with/without adjuvant chemotherapy was performed. Sixty patients from eight neuroendocrine tumor (NET) referral centers, with median follow-up of 23 months (5-187 months) were evaluated. While 28.6% of cases had NET G3, 71.4% had neuroendocrine carcinoma G3 (NEC G3). The 2-year OS rate after radical surgery was 64.5%, with a statistically significant difference in terms of Ki67 threshold (cut-off 55%, P = 0.03) and tumor differentiation (NEC G3 vs. NET G3, P = 0.03). Median RFS after radical surgery was 14 months, and 2-year RFS rate was 44.9%. Use of adjuvant chemotherapy provided no benefit in terms of either OS or RFS in this series. Surgery with radical intent might represent a valid option for GEP-NEN G3 patients with locoregional disease, especially with Ki67 value ≤ 55%.
    Subject(s): Adult ; Aged ; Aged, 80 and over ; Carcinoma, Neuroendocrine - pathology ; Carcinoma, Neuroendocrine - surgery ; Chemotherapy, Adjuvant ; Colectomy ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Digestive System Surgical Procedures - methods ; Disease-Free Survival ; Esophagectomy ; Female ; Gastrectomy ; Gastrointestinal Neoplasms - pathology ; Gastrointestinal Neoplasms - surgery ; Humans ; Ki-67 Antigen ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Staging ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - surgery ; Pancreatectomy ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - surgery ; Pancreaticoduodenectomy ; Platinum Compounds - therapeutic use ; Proctectomy ; Retrospective Studies ; Survival Rate
    ISSN: 1068-9265
    E-ISSN: 1534-4681
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Journal of cancer research and clinical oncology, 2018-07, Vol.144 (7), p.1227-1237
    Description: Glioblastomas represent the most common primary malignant tumor of the nervous system and the most frequent type of astrocytic tumors. Despite improved therapeutic options, prognosis has remained exceptionally poor over the last two decades. Therefore, new treatment approaches are urgently needed. An overexpression of somatostatin (SST) as well as chemokine CXCR4 and endothelin A (ETA) receptors has been shown for many types of cancer. Respective expression data for astrocytic brain tumors, however, are scarce and contradictory.SST subtype, CXCR4 and ETA expression was comparatively evaluated in a total of 57 grade I–IV astrocytic tumor samples by immunohistochemistry using well-characterized monoclonal antibodies.Overall, receptor expression on the tumor cells was only very low. SST5 was the most prominently expressed receptor, followed by SST3, ETA, SST2 and CXCR4. In contrast, tumor capillaries displayed strong SST2, SST3, SST5, CXCR4 and ETA expression. Presence of SST5, CXCR4 and ETA on tumor cells and of SST3, CXCR4 and ETA on microvessels gradually increased from grade II to grade IV tumors. Ki-67 values correlated significantly with CXCR4 expression on tumor cells and with vascular SST3, CXCR4 or ETA positivity. SST5 or CXCR4 positivity of tumor cells and vascular SST3 or CXCR4 expression negatively correlated with patient outcome.Though having some prognostic value, SST, CXCR4 or ETA expression on astrocytic tumor cells is clearly of no therapeutic relevance. Indirect targeting of these highly vascularized tumors via SST3, SST5, CXCR4 or ETA on the microvessels, in contrast, may represent a promising additional therapeutic strategy.
    Subject(s): Adolescent ; Adult ; Aged ; Aged, 80 and over ; Astrocytoma ; Astrocytoma - metabolism ; Astrocytoma - pathology ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain tumors ; Cancer ; Cancer Research ; Child ; Child, Preschool ; CXCR4 ; Endothelin ; Endothelin receptor A ; Female ; Glioblastoma ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioma ; Gliomas ; Hematology ; Humans ; Immunohistochemistry ; Infant ; Internal Medicine ; Male ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Neoplasm Grading ; Oncology ; Receptor, Endothelin A - biosynthesis ; Receptors, CXCR4 - biosynthesis ; Receptors, Somatostatin - biosynthesis ; Somatostatin receptors ; Young Adult
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...